What is REGN's current stock price?

As of now, REGN is trading at $577.95, with a daily change of +0.39%.

What are the risks associated with REGN stock?

REGN Key risk is its Low Risk Level, .

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Earnings Calendar Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

REGN Stock Analysis & IQ Rating | Regeneron Pharmaceuticals

REGN

Regeneron Pharma

$577.95

+$2.26 | +0.39%

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

Headlines

52W High

$ 943.77

MKT CAP

$ 61.26B

52W Low

$ 476.49

VOL

$ 641.03K

P/E Ratio

14.56

AVG VOL

$ 1.07M

RSI

51.60

TREND

Uptrend

REGN Stock IQ

Login to see Regeneron Pharma (REGN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

REGN Target Price

Login to display

Strengths

REGN Rewards

Earnings are forecast to grow

REGN Rewards

Upgraded on attractively valued

REGN Rewards

Trading below its fair value

Chart

$560.75 (+3.07%)

$558.87 (+3.41%)

$484.93 (+19.18%)

$824.48 (-29.90%)

1year

6month

3month

1month

REGN Risk Level

REGN has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

LOW

HIGH

REGN Analysts Opinion

REGN overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

REGN Analysts Opinion

REGN Analysts opinion is positive and also has improved from the past 3 months

REGN Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

75%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

25%

55%

REGN Street Opinion

REGN Street view is bullish but have mixed views on the near-term outlook

REGN Performance Sentiment

Sentiments overview associated with REGN events and the stock performance.

75%

25%

Positive

Negative

27 out of 36
events present

9 out of 36
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$574.23

Resistance
Price

$555.51

Current Price Range

$604.91

Show methods +

Linked to REGN

IQ

Close Price

Change

NVS

4.26

130.36

-0.97%

SNY

4.16

51.64

+4.28%

MRK

4.04

87.49

+0.36%

AZN

4.18

83.29

-0.13%

VRNA

2.50

88.00

+6.02%

REGN Latest Analysis +

REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?. Regenerons Q3 earnings on Oct. 28 will likely spotlight Dupixent profits and strong Eylea HD uptake amid lingering Eylea competition.

Fri Oct 24, 2025

$577.95 | +0.39%

Activity

Canaccord Genuity Maintains Regeneron Pharmaceuticals (REGN) Buy Recommendation. Fintel reports that on October 23 2025 Canaccord Genuity maintained coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) with a Buy recommendation. Analyst Price Forecast Suggests 29.33% Upside

Fri Oct 24, 2025

$577.95 | +0.39%

Rating

Exploring Analyst Estimates for Regeneron (REGN) Q3 Earnings Beyond Revenue and EPS. Evaluate the expected performance of Regeneron (REGN) for the quarter ended September 2025 looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Thu Oct 23, 2025

$575.69 | -1.55%

Earnings

Emphysema Market Analysis Reveals Promising Growth Opportunities and Trends During the Forecast Period (2025-2034) | DelveInsight. The emphysema market is anticipated to grow steadily fueled by a range of emerging therapies under development. Leading candidates like SAR447537 (Sanofi) Alvelestat (Mereo BioPharma) BEAM-302 (Beam Therapeutics) itepekimab (Regeneron Pharmaceuticals/Sanofi) depemokimab (GSK) and...

Tue Oct 21, 2025

$579.34 | +0.45%

Potential

Earnings Preview: Regeneron (REGN) Q3 Earnings Expected to Decline. Regeneron (REGN) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tue Oct 21, 2025

$579.34 | +0.45%

Earnings

Heres How Much $1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today. Regeneron Pharmaceuticals (NASDAQ:) has outperformed the market over the past 20 years by 12.6% on an annualized basis producing an average annual return of 21.67%. Currently Regeneron Pharmaceuticals has a market capitalization of $62.41 billion.

Mon Oct 20, 2025

$576.53 | -0.26%

Activity

Benjamin Graham Detailed Fundamental Analysis - REGN. Below is Valideas guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow REGN rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that hav

Mon Oct 20, 2025

$576.53 | -0.26%

Potential

Benjamin Graham Detailed Fundamental Analysis - REGN. Below is Valideas guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow REGN rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that hav

Fri Oct 17, 2025

$578.05 | +1.56%

Potential

REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss (Revised). Regenerons DB-OTO gene therapy shows hearing gains in nearly all CHORD study participants with durable and meaningful improvements.

Thu Oct 16, 2025

$569.17 | -1.26%

Activity

REGN Factor-Based Stock Analysis - Benjamin Graham. Below is Valideas guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow REGN rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that hav

Wed Oct 15, 2025

$576.42 | +0.67%

Potential

FAQ About REGN Stock Insights

What is REGN current stock price?

What are REGN stock strengths?

What risks are associated with REGN stock?

When is REGN next earnings report?

What is REGN market cap and volume?

What is REGN's current Stock IQ?

Should I buy REGN stock right now?

Is REGN a Strong Buy right now?

What does a 'Strong Buy' rating mean for REGN?

What does a 'Strong Sell' rating mean for REGN?

What factors influence REGN's Stock IQ?

Explore our REGN Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored REGN Stock Strategies
Effective Risk Management

FIND US ON

Receive our REGN Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

REGN

Regeneron Pharma

Current Price

$577.95

+$2.26 | +0.39%

52W High

$ 943.77

MKT CAP

$ 61.26B

52W Low

$ 476.49

VOL

$ 641.03K

P/E Ratio

14.56

AVG VOL

$ 1.07M

RSI

51.60

TREND

Uptrend

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

REGN Rewards

Earnings are forecast to grow

REGN Rewards

Upgraded on attractively valued

REGN Rewards

Trading below its fair value

Linked to REGN

Symbol

IQ

Close

Change

NVS

4.26

130.36

-0.97%

SNY

4.16

51.64

+4.28%

MRK

4.04

87.49

+0.36%

AZN

4.18

83.29

-0.13%

VRNA

2.50

88.00

+6.02%

REGN Stock IQ

Login to unlock Regeneron Pharma (REGN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Chart

$560.75 (+3.07%)

$558.87 (+3.41%)

$484.93 (+19.18%)

$824.48 (-29.90%)

1year

6month

3month

1month

REGN Analysts Opinion

REGN Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

REGN Analysts Opinion

REGN Analysts opinion is positive and also has improved from the past 3 months

REGN Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

75%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

25%

55%

REGN Street Opinion

REGN Street view is bullish but have mixed views on the near-term outlook

REGN Risk Level

REGN has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

LOW

HIGH

REGN Performance Sentiment

Sentiments overview associated with REGN events and the stock performance.

75%

25%

Positive

Negative

27 out of 36
events present

9 out of 36
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$574.23

Resistance
Price

$555.51

Current Price Range

$604.91

Show methods +

REGN Latest Analysis

REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?. Regenerons Q3 earnings on Oct. 28 will likely spotlight Dupixent profits and strong Eylea HD uptake amid lingering Eylea competition.

Fri Oct 24, 2025

$577.95 | +0.39%

Activity

Canaccord Genuity Maintains Regeneron Pharmaceuticals (REGN) Buy Recommendation. Fintel reports that on October 23 2025 Canaccord Genuity maintained coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) with a Buy recommendation. Analyst Price Forecast Suggests 29.33% Upside

Fri Oct 24, 2025

$577.95 | +0.39%

Rating

Exploring Analyst Estimates for Regeneron (REGN) Q3 Earnings Beyond Revenue and EPS. Evaluate the expected performance of Regeneron (REGN) for the quarter ended September 2025 looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Thu Oct 23, 2025

$575.69 | -1.55%

Earnings

Emphysema Market Analysis Reveals Promising Growth Opportunities and Trends During the Forecast Period (2025-2034) | DelveInsight. The emphysema market is anticipated to grow steadily fueled by a range of emerging therapies under development. Leading candidates like SAR447537 (Sanofi) Alvelestat (Mereo BioPharma) BEAM-302 (Beam Therapeutics) itepekimab (Regeneron Pharmaceuticals/Sanofi) depemokimab (GSK) and...

Tue Oct 21, 2025

$579.34 | +0.45%

Potential

Earnings Preview: Regeneron (REGN) Q3 Earnings Expected to Decline. Regeneron (REGN) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tue Oct 21, 2025

$579.34 | +0.45%

Earnings

Heres How Much $1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today. Regeneron Pharmaceuticals (NASDAQ:) has outperformed the market over the past 20 years by 12.6% on an annualized basis producing an average annual return of 21.67%. Currently Regeneron Pharmaceuticals has a market capitalization of $62.41 billion.

Mon Oct 20, 2025

$576.53 | -0.26%

Activity

Benjamin Graham Detailed Fundamental Analysis - REGN. Below is Valideas guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow REGN rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that hav

Mon Oct 20, 2025

$576.53 | -0.26%

Potential

Benjamin Graham Detailed Fundamental Analysis - REGN. Below is Valideas guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow REGN rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that hav

Fri Oct 17, 2025

$578.05 | +1.56%

Potential

REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss (Revised). Regenerons DB-OTO gene therapy shows hearing gains in nearly all CHORD study participants with durable and meaningful improvements.

Thu Oct 16, 2025

$569.17 | -1.26%

Activity

REGN Factor-Based Stock Analysis - Benjamin Graham. Below is Valideas guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow REGN rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that hav

Wed Oct 15, 2025

$576.42 | +0.67%

Potential

Discover REGN Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of REGN. We're here to help you make informed investment decisions today.

FIND US ON

Receive our REGN Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

REGN Stock trends

REGN Stock performance

REGN Stock analysis

REGN investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing REGN

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing REGN

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

REGN Stock Analysis & IQ Rating | Regeneron Pharmaceuticals

REGN Stock IQ

REGN Target Price

REGN Risk Level

REGN Analysts Opinion

REGN Street Consensus

REGN Performance Sentiment

Technical Price Levels

Explore our REGN Stock insights

Receive our REGN Daily Alerts

REGN Stock IQ

REGN Street Consensus

REGN Risk Level

Technical Price Levels

Discover REGN Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of REGN. We're here to help you make informed investment decisions today.

Receive our REGN Daily Alerts

REGN Runner Alarm